



Pseudotyped Luciferase rSARS-CoV-2 Spike, S477N (Australian mutation, Hodcroft 2020 (COVL-S477N)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview

SARS-CoV-2 Pseudovirus (S477N /Australian mutation, Hodcroft 2020) are used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV-2 spike protein. Pseudovirus display antigenically correct spike protein pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core. Pseudovirus are capable of a single round of infection and carry a genome that expresses Luciferase optical reporter gene upon infection. Pseudovirus are produced in HEK293T cells using three separate plasmids, encoding the spike protein (S477N, D614G), a lentiviral gag polyprotein, and a reporter gene. Pseudovirus are created using a second-generation lentiviral system with components that are highly unlikely to recombine to produce a fully infectious virus (requiring 3 separate recombination events to do so). However, lentiviruses are capable of genomic integration and Pseudovirus are derived from biological materials so should be handled with caution within a BSL2 or enhanced BSL2 laboratory environment.

Species	SARS-CoV-2 (S477N, D614G)
Size	1 ml
Storage	Store at -80°C. Multiple freeze/thaw cycles not recommended. When using the virus, transfer the virus from the -80 ° C refrigerator and melt it in an ice bath.
Ship	Frozen on dry ice